The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders

Expert Opinion on Drug Discovery

Volumn 8, Issue 9, 2013, Pages 1165-1179

  Roskoski Jr , Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

Anaplastic lymphoma kinase; C Met; Epidermal growth factor receptor; Hsp90; Lung cancer; Protein kinase; Structure based drug design; Targeted cancer therapy

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANTINEOPLASTIC AGENT; CRIZOTINIB; HYBRID PROTEIN; PHA 0665752; PROTEIN EML 4; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 84883017405     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.813015     Document Type: Review

References (92)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
3. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: Diagnosis and management. Am Fam Physician 2007;75:56-63 (Pubitemid 46064483)
4. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132(3 Suppl):1S-19S (Pubitemid 47502795)
5. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25
6. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
8. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703; Erratum in: N Engl J Med 2011;364:588
9. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011;364:947-55
10. Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors: A new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013;8:55-67
11. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62
12. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6 (Pubitemid 47206930)
13. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203 (Pubitemid 350235027)
14. Dai Z, Kelly JC, Meloni-Ehrig A, et al. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. Mol Cytogenet 2012;5:44
15. Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63
16. Shaw AT, Engelman JA. ALK in Lung cancer: Past, present, and future. J Clin Oncol 2013;31:1105-11
17. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34 (Pubitemid 35425239)
18. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711 (Pubitemid 38748887)
19. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34
20. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995;267:316-17
21. Tabbò F, Barreca A, Piva R, Inghirami G; European T-Cell Lymphoma Study Group. ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Onco 2012;2:41
22. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997;14:2175-88; Erratum in: Oncogene 1997;15:2883 (Pubitemid 27248229)
23. Mano H. ALKoma: A cancer subtype with a shared target. Cancer Discov 2012;2:495-502
24. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-9
25. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002;277:35990-8
26. Motegi A, Fujimoto J, Kotani M, et al. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004;117:3319-29 (Pubitemid 39139916)
27. Moog-Lutz C, Degoutin J, Gouzi JY, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280:26039-48 (Pubitemid 41022195)
28. Trusolino L, Bertotti A, Comoglio PM. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48
29. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
30. Peters S, Adjei AA. MET: A promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26
31. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 2012;12:89-103
32. Gao J, Inagaki Y, Song P, et al. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res 2012;65:23-30
33. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: Progress and challenges. Trends Mol Med 2010;16:37-45
34. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55 (Pubitemid 30175676)
35. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111-20 (Pubitemid 32221803)
36. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213 (Pubitemid 46679285)
37. Taylor SS, Kornev AP. Protein kinases: Evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36:65-77
38. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988;241:42-52
39. Kornev AP, Taylor SS. Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 2010;1804:440-4
40. Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006;103:17783-8 (Pubitemid 44852237)
41. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82 (Pubitemid 34606870)
42. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64 (Pubitemid 43936934)
43. Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 2010;430:425-37
44. Bossi RT, Saccardo MB, Ardini E, et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010;49:6813-25
45. Roskoski R Jr. Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 2013;68:68-94
46. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: Signalling in development and disease. Biochem J 2009;420:345-61
47. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90 (Pubitemid 350042396)
48. Smith GF. Medicinal chemistry by the numbers: The physicochemistry, thermodynamics and kinetics of modern drug design. Prog Med Chem 2009;48:1-29
49. Roskoski R Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res 2012;66:105-43
50. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22
51. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17 (Pubitemid 46815090)
52. Sun Y, Nowak KA, Zaorsky NG, et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Mol Cancer Ther 2013;12(5):696-704
53. Tumati V, Kumar S, Yu L, et al. Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep 2013;29:1094-100
54. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011-19
55. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004;61:2939-53 (Pubitemid 40104592)
56. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-77
57. Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:812-26; Erratum in: J Clin Oncol 2009;27:3070-1
58. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17
59. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
60. Choi YL, Soda M, Yamashita Y, et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
61. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the gatekeeper door: Exploiting the active kinase conformation. J Med Chem 2010;53:2681-94
62. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53 (Pubitemid 40446252)
63. Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011;2011:165214
64. Azam M, Seeliger MA, Gray NS, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008;15:1109-18
65. Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71:4920-31
66. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33
67. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29
68. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non- Hodgkin's lymphoma. N Engl J Med 2008;359:613-26
69. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76
70. Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl) 2007;85:863-75 (Pubitemid 47077107)
71. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4
72. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8
73. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70
74. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5
75. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011;71:4403-11
76. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358
77. Brzezniak C, Carter CA, Giaccone G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013;14:247-53
78. Heuckmann JM, Balke-Want H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:4682-90
79. Ahsan A, Ramanand SG, Whitehead C, et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012;14:670-7
80. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: Where do we stand now and where are we headed? Cancer Biol Ther 2012;13:247-63
81. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26 (Pubitemid 33653411)
82. Smith GF. Medicinal chemistry by the numbers: The physicochemistry, thermodynamics and kinetics of modern drug design. Prog Med Chem 2009;48:1-29
83. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7
84. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74
85. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9
86. Roskoski R Jr. STI-571: An anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003;309:709-17 (Pubitemid 37122587)
87. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-15 (Pubitemid 41608395)
88. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70
89. Lovly CM, Pao W. Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Sci Transl Med 2012;4(120):120ps2
90. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
91. Heuckmann JM, H€olzel M, Sos ML, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011;17:7394-401
92. Pfizer Oncology ODAC Pediatric Subcommittee Meeting held on the November 30. 2010.Available from: Www.fda.gov/ downloads/advisorycommittees/ committeesmeetingmaterials/drugs/ oncologicdrugsadvisorycommittee/ ucm236391.pdf